Author Correction: Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells

Affiliations

• ¹ Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
• ² Department of Medicine, The University of California San Diego, La Jolla, CA, USA.
• ³ Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
• ⁴ Faculty of Bioengineering and Bioinformatics, Moscow Lomonosov State University, Moscow, Russia.
• ⁵ Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
• ⁶ IAVI Neutralizing Antibody Center (IAVI), The Scripps Research Institute, La Jolla, CA, USA.
• ⁷ Faculty of Science, University of Ottawa, Ottawa, Canada.
• ⁸ Department of Biochemistry, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Madrid, Spain.
• ⁹ Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA.
• ¹⁰ Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. [email protected].
• ¹¹ Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. [email protected].
• ¹² Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. [email protected].
• ¹³ IAVI Neutralizing Antibody Center (IAVI), The Scripps Research Institute, La Jolla, CA, USA. [email protected].
• ¹⁴ Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA. [email protected].
• ¹⁵ Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. [email protected].
• ¹⁶ Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. [email protected].